Asmodius. I am neither giving you propaganda nor
am I partisan to socialised medicine. I repeat. Go
to Canada, as I do every week to shop, and ask the
average Canadian if he wants to swap his health care for
the american system.
You take a position then fit
in the facts. Try gathering some facts and then
coming to a conclusion.
My contention is that this
system is probably coming and ABT will have to fit into
it and even try make it an advantage.
<<<JNJ is what I have been saying all
along. Perfect fit both on the pharmaceuticaland the
dianositic end...or let me say what is left of the diagnosic
business. I own a lot of stock and have hung in there. This
week should be interesting...could be good or bad.
Ecdan00, I came back to
your 1/13 post. I've been buckled up but I haven't
seen or heard anything yet. I'm ready for ANYTHING to
happen that will get ABT stock price out of the toilet!
Anything of promis up?
I own both stocks also. Agree benefits of a
merger are questionable. My point is not to put too much
stock in the protestations of ABT as similar denials
issued forth from Pfe's CEO when he was asked about
Within days, Mr Steere made his
hostile bid for Warner Lambert.
Forget JNJ - it's CEO, Ralph Larsen made it clear
that JNJ does not have to merge for growth (its
internal growth rate is superb - better than ABT's with a
much more "state of the art" pharmaceutical division
in R&D processes). However, he is interested in
select biotech businesses for JNJ's pharma division
going forward though. And ABT is certainly not a
And Ross...if it couldn't be sold
outright, it could be spun-off. ABT's neighbor Baxter has
been good at that with their "non-strategic" business
units. But it may not serve a larger interest to do
this. While consumer pharma margins are well below the
commercial pharma product lines, they are at par or above
those in the hospital products or (especially)
diagnostics product lines. And considering consumer pharma
product's cash generation ability as well, from a treasury
management perspective, it wouldn't necessarily be of
benefit to do anything with Ross within the current
business structure of ABT.
It has been speculated that previous management had falling out with Takeda as evident by Takeda taking its promising diabetes drug to LLY and not to TAP. Hope present management has mended fences.
i'm interested in all the talk of selling the
ross division. i always thought that the ross division
was the cash cow of abbott. if they are not, who
would be interested in buying a lame-duck business
unit? also, where did all this jnj merger talk begin?
i'd like to know if there is a sniff of a chance of
that or any other merger with the state of abbott?
Thanks for your interesting comments.
believe No. 1 is a real possibility if Miles White comes
under enough pressure. The Business Week feature
mentioned that some analysts think the Ross Division needs
to go as a move to get ABT back to its core
business. Nos. 2, 3, and 4 are practical ideas; we can
always hope that within top management there are some
cool heads presenting workable plans like
The TAP joint venture appears to be one of ABT's more
successful endeavors, and ABT's relationship with Takeda is
one of long standing. I'm wondering what the chances
are that Takeda, a huge company itself, may be
looking at something more than just a partnership with
I would hope some consolidation has
already begun. This company has a lot of cleanup and
belt-tightening to do.